Drugs / GSM-779690T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07155980 | Nov 2025 → Jul 2026 | — | Acta Pharmaceuticals | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07690228 Comparator | Aug 2026 overdue | Alzheimer disease | Acta Pharmaceuticals | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSM-779690T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07690228 ↗ |
| Route | Oral | “receive a single oral dose of GSM-779690T” NCT07155980 ↗ |